Phathom Pharmaceuticals Inc (PHAT)
10.25
-0.08
(-0.77%)
USD |
NASDAQ |
Jun 26, 14:24
Phathom Pharmaceuticals Revenue (Quarterly): 1.912M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 1.912M |
Date | Value |
---|---|
December 31, 2023 | 0.682M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.682M
Minimum
Dec 2023
1.912M
Maximum
Mar 2024
1.297M
Average
1.297M
Median
Revenue (Quarterly) Benchmarks
Insmed Inc | 75.50M |
Regeneron Pharmaceuticals Inc | 3.145B |
Rocket Pharmaceuticals Inc | -- |
Rhythm Pharmaceuticals Inc | 25.97M |
Xeris Biopharma Holdings Inc | 40.64M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -82.85M |
Total Expenses (Quarterly) | 71.87M |
EPS Diluted (Quarterly) | -1.42 |
Enterprise Value | 432.63M |
Gross Profit Margin (Quarterly) | 77.72% |
Profit Margin (Quarterly) | -4.33K% |
Earnings Yield | -43.61% |